Glucocorticoid-induced alterations of renal sulfate transport.

Glucocorticoid administration decreases renal sodium/phosphate cotransport in the proximal tubule due to a down-regulation of the sodium/phosphate cotransporter but has no effect on the sodium-dependent transport of glucose or proline. The objectives of the present investigation were to determine the effects of the glucocorticoid methylprednisolone (MPL) on 1) inorganic sulfate renal clearance in rats in vivo, 2) sodium/sulfate cotransport in kidney cortex membrane vesicles, and 3) the cellular mechanism of the MPL-induced alterations in sulfate renal transport. Male adrenalectomized Wistar rats received an i.v. dose of 50 mg/kg MPL or the vehicle. Urine samples were collected for 12 h after the administration of MPL, and blood samples were collected at the midpoint of the urine collection. Other animals were sacrificed at 4, 6, and 12 h after MPL administration, and the kidney cortex was removed for RNA or membrane preparations. Kidney cortex sodium/sulfate cotransporter (NaSi-1) mRNA levels were determined by reverse transcription-polymerase chain reaction and NaSi-1 protein levels were determined by enzyme-linked immunosorbent assay. The urinary excretion rate and renal clearance of sulfate were significantly increased in MPL-treated animals (144.0 +/- 27.0 versus 65.3 +/- 21.3 micromol/12 h/kg and 0.208 +/- 0.038 versus 0. 078 +/- 0.025 ml/min/kg, mean +/- S.E., n = 9-12 in treated versus control). The V(max) value for sodium-dependent sulfate transport in brush border membrane vesicles (representing reabsorption in the proximal tubules) was significantly decreased in MPL-treated animals compared with controls (0.68 +/- 0.07 versus 0.88 +/- 0.05 nmol/mg of protein/10 s, mean +/- S.E.). There was no change in the K(m) value for sodium/sulfate cotransport in brush-border membrane and no change in sulfate/anion exchange in basolateral membrane vesicles. Membrane fluidity in brush border membrane and basolateral membrane vesicles, determined by the fluorescence polarization of 1, 6-diphenyl-1,3,5-hexatriene was unaltered by MPL treatment. NaSi-1 mRNA levels were significantly decreased at 4 and 6 h, but not 12 h, after MPL administration, whereas NaSi-1 protein expression was significantly decreased at 4, 6, and 12 h. Therefore, MPL treatment increases the renal clearance of inorganic sulfate, at least in part, due to down-regulation of NaSi-1 mRNA and protein expression in the kidney.

In-vivo activity of retinoid esters in skin is related to in-vitro hydrolysis rate.

BMS-181163 (4-acetamidophenyl retinoate, previously reported as BMY-30123), the acetamidophenyl ester of all-trans-retinoic acid (tRA), is topically active in various retinoid-sensitive animal models, but was recently shown to be ineffective for the treatment of acne in patients. To determine whether BMS-181163 functions as a prodrug of tRA in mice but not in man, the relative rates of ester hydrolysis in mouse and human skin homogenates were determined. In-vitro hydrolysis assays showed that BMS-181163 was substantially hydrolysed in mouse skin homogenates and minimally in human skin preparations. In addition, a series of phenyl esters of tRA and several known active synthetic retinoids (Ch-80: (E)-4-[3-oxo-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1 - propenyl] benzoic acid; CD-271: 6-[3-(1-adamantyl)-4-methyoxyphenyl]-2-naphthoic acid; and TTNPB: (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1- propenyl] benzoic acid) was prepared and hydrolysis rates and in-vivo (rhino mouse utriculi reduction) activities were compared. The hydrolysis rates of the six test retinoid phenyl esters, ranging from 0.06 to 2.0 h-1 were found to correlate with the in-vivo activity. Those esters (BMS-181163 and acetamidophenyl esters of Ch-80 and TTNPB) with a higher hydrolysis rate exhibited in-vivo activity only slightly lower than their parent free acid retinoids. In contrast, the three phenyl esters with a hydrolysis rate less than 0.3 h-1 were inactive in-vivo.(ABSTRACT TRUNCATED AT 250 WORDS)

Inhibitor of phospholipase A2 blocks eicosanoid and platelet activating factor biosynthesis and has topical anti-inflammatory activity.

The effect of a phospholipase A2 (PLA2) inhibitor on leukotriene, prostaglandin and platelet activating factor (PAF) biosynthesis in isolated cells and in vivo was determined. BMS-181162, [4(3'-carboxyphenyl)-3,7-dimethyl-9(2",6",6"-trimethyl-1"- cyclohexenyl)2Z,4E,6E,8E-nonatetraenoic acid], reversibly inhibited the 14-kdalton PLA2 purified from human synovial fluid with an IC50 of 8 microns. In A23187-stimulated human polymorphonuclear leukocytes (PMNs), BMS-181162 blocked arachidonic acid release with an IC50 of 10 microns. Leukotriene B4 and PAF biosynthesis in these cells was also inhibited. In a phorbol ester-induced chronic mouse skin inflammation model, topically applied BMS-181162 markedly lowered the tissue levels of leukotriene B4 and prostaglandin E2 and dose-dependently inhibited leukocyte infiltration (ED50 = 180 micrograms per ear). BMS-181162 is an inhibitor of PLA2 and may prove to be a useful tool in the delineation of the role of PLA2 in the inflammatory process.

Salicylate inhibits the renal transport of inorganic sulfate in rat membrane vesicle preparations.

Salicylic acid (SA) administration produces a pronounced enhancement of the renal clearance of inorganic sulfate in rats. The purpose of the present investigation was to determine if SA inhibits the renal transport of inorganic sulfate in rat kidney cortex brush border membrane (BBM) and basolateral membrane (BLM) vesicle preparations. Sodium-dependent cotransport of inorganic sulfate was examined in BBM, and the values for KM and Vmax, determined using nonlinear regression analysis, were 0.52 +/- 0.41 mM and 2.84 +/- 1.26 nmol/mg protein/10 sec, respectively (N = 7). Bicarbonate-dependent sulfate anion exchange was examined in BLM, and the values for KM and Vmax were 0.31 +/- 0.14 mM and 0.83 +/- 0.27 nmol/mg protein/10 sec, respectively (N = 5). SA inhibited sulfate transport into both BBM and BLM preparations. The Ki values, fitted using both competitive and noncompetitive inhibition models, were 19.4 +/- 9.2 and 26.3 +/- 12.2 mM (N = 3), respectively, for sodium/sulfate cotransport in BBM vesicles and 1.10 +/- 0.32 and 1.93 +/- 0.38 mM (N = 3), respectively, for bicarbonate-driven sulfate transport in BLM vesicles. Because SA did not transstimulate sulfate transport into vesicle preparations, this might suggest a noncompetitive inhibition mechanism. The inhibitory effect of SA appears to occur predominantly at the BLM membrane, due to the lower Ki observed in the transport studies. Therefore, the results demonstrate that SA predominantly inhibits the transport of inorganic sulfate across the renal BLM; this interaction may be responsible, at least in part, for the SA-induced increase in sulfate renal clearance that has been observed in vivo.

Evaluation of "true" creatinine clearance in rats reveals extensive renal secretion.

The renal clearance of endogenous creatinine is widely used to assess glomerular filtration rate (GFR) and renal function in animal investigations. The objective of the present investigation was to evaluate the extent of renal secretion of endogenous creatinine in rats and the effect of probenecid, the classical inhibitor of organic anion transport, on creatinine clearance. Ten female Lewis rats received 3H-inulin (5-muCi i.v. bolus followed by 5 muCi/hr) throughout a 6-hr period. Three hours after initiation of the inulin infusion, probenecid was administered (92.4-mg/kg i.v. bolus followed by 0.59 mg/min/kg). Steady-state serum concentrations of about 500 micrograms/ml probenecid were achieved. Renal clearance was assessed between 1 and 3 hr (control) and between 4 and 6 hr (probenecid treatment). A preliminary study in seven rats demonstrated no time-dependent change in inulin or creatinine clearance between these two study intervals. Creatinine clearances were determined by an alkaline picrate assay which incorporated Fuller's earth (Lloyd reagent) to remove interfering noncreatinine chromogens from serum samples and these values were compared with those using a nonspecific picrate assay. "True" clearance ratios of creatinine to inulin (Clcr/CLin) were greater than unity (2.33 +/- 0.83, mean +/- SD) and were significantly decreased after probenecid treatment (1.26 +/- 0.28, P less than 0.01). Probenecid had no effect on GFR, as assessed by inulin clearance. Using the nonspecific picrate assay, CLcr/CLin was 1.12 +/- 0.41, which was not significantly different from unity and which decreased to 0.53 +/- 0.12 after probenecid treatment. Therefore, creatinine undergoes extensive renal secretion in female Lewis rats.

Sulfate homeostasis. IV. Probenecid-induced alterations of inorganic sulfate in rats.

Homeostasis of inorganic sulfate is maintained by the capacity-limited renal reabsorption of sulfate in the proximal tubule. The purpose of the present investigation was to determine if probenecid, the classical inhibitor of renal organic anion secretion, may affect sulfate renal clearance. Two groups of rats were administered in a randomized crossover design, an i.v. bolus dose (20.6 or 92.4 mg/kg) and 4-hr infusion (0.28 or 0.59 mg/min/kg) of probenecid or vehicle, and blood and urine samples were collected. At a steady-state serum concentration of 0.45 mM, probenecid had no significant effect on the serum concentrations or renal clearance of inorganic sulfate, whereas at a serum concentration of 1.4 mM, probenecid treatment caused a significant decrease in serum sulfate concentrations (0.57 +/- 0.11 vs 0.96 +/- 0.19 mM in controls, mean +/- SD, n = 6, P less than 0.001) due to an increase in the renal clearance of sulfate (3.88 +/- 1.18 vs 2.13 +/- 0.84 ml/min/kg in controls, P less than 0.01). The fraction of the filtered sulfate that was reabsorbed was significantly decreased (0.38 +/- 0.23, vs 0.74 +/- 0.09 in controls, P less than 0.01). Therefore, probenecid treatment results in the inhibition of the renal reabsorption of inorganic sulfate in rats in vivo.

Comparison of assay procedures used to measure total and unbound concentrations of quinidine.

Individualized quinidine dosing through the assessment of serum concentrations is warranted because of the wide variability observed in its pharmacokinetic behavior and its reported narrow therapeutic index. The free fraction of quinidine also varies widely. Thus the development of procedures that could be widely used to determine quinidine free concentrations would be highly desirable. It was the purpose of this study to evaluate several procedures available to determine total serum quinidine concentrations (rate nephelometry [ICS], homogenous enzyme immunoassay [EMIT], and high-performance liquid chromatography [HPLC]). Furthermore, in samples from 46 patients, equilibrium dialysis and ultrafiltration procedures were compared for their ability to estimate quinidine free fraction. Finally, unbound concentrations of quinidine were compared using a modified EMIT procedure and a standard HPLC method to quantitate quinidine in ultrafiltrates from patient samples. For the measurement of total quinidine concentrations, reasonable agreement was seen when EMIT and ICS systems were compared with HPLC (ICS = 1.03.HPLC + 0.96, r = 0.93; EMIT = 1.08.HPLC + 0.38, r = 0.93) The mean errors, however, for these procedures were high (ICS +70 percent, range +7 to +233 percent; EMIT +35 percent, range 0 to 110 percent). Quinidine free fractions (QFF) determined by equilibrium dialysis (E) and ultrafiltration (U) showed good agreement (QFF(U) = 1.11.QFF(E) +0.0; r = 0.96). Unbound quinidine concentration determined by EMIT analysis of ultrafiltrate substantially overestimated the values obtained by HPLC analysis (mean error by EMIT 104 +/- 59 percent). It is concluded that HPLC is the method of choice for determining both total and unbound serum quinidine concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)